# Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

> **NCT00945139** · PHASE2 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 46 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Doxil
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT00945139
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-12
- **Final completion:** 2011-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00945139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00945139, "Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00945139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*